Empagliflozin has demonstrated to be cost saving when added to standard of care in other countries but, what about South Africa? In the Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa, Professor Jacques Snyman investigates Empagliflozin's financial impact on top of usual care and answers this and many others question.